Vaccination with the 7 selected peptide combination was screened to see if it could provide tumour therapy in the B16 tumour model constitutively expressing HLA-DP4 (B16cDP4) or expressing DP4 under an IFNγ inducible promoter (B16iDP4). This evidence concerns the gene IFNG and neoplasm.